Telerehabilitation Alzheimer's Disease Feasibility (TADF) (TADF)

Telerehabilitation Combining Virtual Reality Adaptable Games and Drug Therapy for Early Alzheimer's Disease - Feasibility

This is a pilot RCT with equal arms: experimental arm and (wait list) control arm.

All participants will be in the early stage of Alzheimer's disease and on stable medication. They will all continue with this medication for their 6 months participation.

Experimental group will add weekly training on the experimental device, 5 days a week for 8 weeks. Training will involve therapeutic games aimed primarily at the memory cognitive domain. All participants will receive weekly calls from clinical coordinator and report on medication and overall health. Caregivers will also be enrolled so they support the trials.

Study Overview

• Status: Recruiting
• Conditions: Alzheimer Disease; Healthy Aging
• Intervention / Treatment: Device: BrightGo cognitive training; Drug: Standard of Care medication for early Alzheimer's Disease

Detailed Description

Participants will be randomized equally into an experimental group and a wait list control group.

Experimental training will occur in the home, and will last 8 weeks, each week having 5 sessions of therapeutic game play. Each session will start with vitals being measured and logged followed by motor and biosensor baselines. Subsequently, participants will play an increasing number of games, targeted at the major cognitive domains of memory (primarily), attention and executive functions. Since sessions will increase in length, researchers expect that more than 10 short games may eventually be played in each session.

This will be an ABAA protocol for the experimental group, and a AABA protocol for the wait-list control group. Data will be sampled at baseline (A), during each rehabilitation session (B), mid-way through the study (at 2 months from baseline) and at the end of the study, at 4 months from baseline (A).

At the end of every 4 weeks of BrightGo training, the participant and caregiver will each fill a custom subjective evaluation questionnaire.

Before crossover to the experimental protocol, participants in the wait-list group will continue with their daily routine and prescribed medication (which will be logged). After crossing over, they will add the BrightGo intervention to their daily routine.

Participants initially randomized to the experimental group will continue with daily routine and medication, and add the 5 sessions per week of experimental therapy. Once they cross over to the control arm after 8 weeks from start, they will continue with their daily routine and prescribed medication (which will again be logged) for another 8 weeks.

All participants will receive a weekly call from the Clinical Coordinator so to report on any health concerns and system issues, as well as medication use. Caregivers will also be enrolled so they support the trials.

• Study Type: Interventional
• Enrollment (Anticipated): 14
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Grigore C Burdea, PhD; Phone Number: 9084069334; Email: diplomatru@yahoo.com
• Study Contact Backup: Name: Edward A Berde, MS; Phone Number: 7326400400; Email: ed@brightcloud.health

Study Locations

• United States
  • New Jersey
    • New Brunswick, New Jersey, United States, 08901-2066
      • Recruiting
      • Rutgers, The State University of New Jersey
      • Contact: Jasdeep S Hundal, PsyD; Phone Number: 732-235-6332; Email: jsh164@rwjms.rutgers.edu
      • Contact: Daniel Valdivia, B.S.; Phone Number: 2013164424; Email: djv85@gsbs.rutgers.edu
      • Principal Investigator: Jasdeep S Hundal, PsyD
    • North Brunswick, New Jersey, United States, 08902
      • Recruiting
      • Bright Cloud Int'l Corp
      • Contact: Grigore C Burdea, PhD; Phone Number: 908-406-9334; Email: diplomatru@yahoo.com
      • Contact: Edward A Berde, MS; Phone Number: 732-640-0400; Email: ed@brightcloud.health
      • Principal Investigator: Grigore C Burdea, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years to 85 years (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age 65 to 85;
• Diagnosis of early Alzheimer's (Montreal Cognitive Assessment [MoCA] score of 19-25) [Nasreddine et al 2005].
• English speakers;
• Ability to actively move UE and to flex/extend fingers;
• Stable on Aricept 10 mg daily intake or Exelon 9.5 mg patch medication
• Able to consent;
• Living in the community in Central Jersey so to facilitate researchers travel to home for system installation and/or repairs,
• Living with a caregiver willing to support trials and be present during sessions;
• Good upper extremity motor function, close to full range of movement of arms and fingers.

Exclusion Criteria:

• Those younger than 65;
• Participating in other research studies;
• Severe visual impairments or legally blind;
• Severe hearing loss or deafness;
• Uncontrolled hypertension (>190/100 mmHg);
• Severe cognitive delay (MoCA <19);
• non-English speakers;
• Those unable to provide consent;
• Unable to move arms and fingers, or with severe arthritis;
• Severe propensity to simulation sickness;
• Those who are not cooperative with the evaluations pre-study ;
• Those who cannot produce reliable scores on the neuropsychological pre-study assessment because they do not comprehend the test, or have severe speech impairment;
• Those not living with a caregiver willing to support trials, and caregiver unwilling or unable to be present during sessions;
• Those that are unwilling allow home inspections to ascertain internet conditions in the home, to determine best placement for the experimental system, to install and remove system, and to provide repairs if needed.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Standard of care medication for early Alzheimer's disease and BrightGo device cognitive training; Participants randomized to the experimental group will have standard of care and 8 weeks of experimental computer-based therapy on the device. Then they will cross over in the control arm. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.	Device: BrightGo cognitive training; Training on the BrightGo experimental device in the home; Other Names: Gamification for cognitive therapy; Drug: Standard of Care medication for early Alzheimer's Disease; Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease; Other Names: Aricept 10 mg daily or Exelon 9.5 mg patch
Other: Standard of care medication for early Alzheimer's disease; Wait list controls will have standard of care only, before they cross over into the experimental group for BrightGo therapy. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.	Drug: Standard of Care medication for early Alzheimer's Disease; Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease; Other Names: Aricept 10 mg daily or Exelon 9.5 mg patch

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in visual attention as measured by Neuropsychological Assessment Battery	Visual attention measured with the dots test of the Neuropsychological Assessment Battery (NAB). This is a delayed recognition span paradigm, in which an array of dots is exposed for a brief period, followed by a blank interference page, followed by a new array with one additional dot. The subject needs to point to the "new" dot. Test administered 3 times, minimum score 0 (none of the new dots found) to maximum 3 (all 3 new dots found). [Hartman 2006]	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Controlled Oral Word Change in language and executive function as measured by the Association Test (CFL/PRW) of the Multilingual Aphasia Examination	measure of language and executive function [Benton & Hamsher, 1994]	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Change in Cognitive executive function assessment score	Trail Making Test B (TMT-B), NAB Executive Functioning Module. This is a timed test (seconds) with less time indicative of better executive function [Raitan 1958]	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Change in verbal memory as measured by Hopkins Verbal Learning Test, Revised (HVLT-R)	Hopkins Verbal Learning Test, Revised (HVLT-R) is a measure of verbal memory. It provides a brief assessment of immediate recall, delayed recall and delayed recognition. Subject is read a series of nouns in several categories, and the asked t repeat these nouns by writing them on a piece of paper. The test is repeated three times, and each time the score is a count of how many nouns were remembered by the subject. The second phase of the test involves delayed recall, which is administered after about 20 minutes from the original test. subject needs to write down all the nouns they remembered and these are counted. There is a maximum of 12 correct responses during delayed recall, so max score is 12 [Brandt 1991]	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Change in visuospatial memory as measured by Brief Visuospatial MemoryTest, Revised (BVMT-R)	BVMT-R is a measure of visuospatial memory. In three Learning Trials, the subject views a stimulus page showing an geometric figure for 10 seconds, and there are 6 drawings presented. Then the subject is asked to draw as many of the figures as possible in their correct location on a page in the response booklet. A Delayed Recall Trial is administered after a 25-minute delay. Last, a Recognition Trial, in which the respondent is asked to identify which of 12 figures were included among the original geometric figures, is administered. Raw scores will be used, with higher numbers representing better outcomes [Benedict et al., 1996].	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Change in Beck Depression Inventory II (BDI II) score, a measure of depression severity	participants' depression measure with higher scores indicating higher severity (worse mood). Score range is 0 to 63, with 0 indicating normal mood (no depression), 1-13 minimal depression, 14-19 mild depression, 20-28 for moderate and 29-63 severe depression.[Beck 1996]	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the participant's quality of life as measured by the Quality of Life in Alzheimer's Disease Patient Version (QoL-AD)	Questionnaire measures Quality of life for AD individuals (QoL-AD) [Longsdon 1996] The questionnaire has 13 items, each with a 4 possible outcomes (poor 1 point to Excellent 4 points). The score trance is 13 (worst) to 52 points representing the best outcome.	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Functional Activities Questionnaire in Older Adults with Dementia	Questionnaire for AD patient independence in daily activities [Mayo 2016] The questionnaire has 10 items, each with a 4 possible outcomes (normal 0 points to Dependent 3 points). The score trance is 0 (best outcome) to 30 points representing the worst outcome.	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Test of Premorbid Functioning (TOPF)	The Advanced Clinical Solutions Test of Premorbid Functioning (TOPF) is a word reading test.	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Controlled Oral Word Association Test (CFL/PRW) of the Multilingual Aphasia Examination	Test measures Language and executive function [Benton & Hamsher, 1994] RANGE	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Categorical verbal fluency (Animal Naming)	Test measures Language and executive function [Tombaugh et al., 1999] RANGE	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Quality of Life in Alzheimers Disease (QoL-AD), Family Version	The Quality of Life in Alzheimers Disease (QoL-AD) is comprised of 13 items (physical health, energy, mood, living situation, memory, family, marriage, friends, self as a whole, ability to do chores, ability to do things for fun, money and life as a whole). Response options include 1(poor), 2(fair), 3(good) and 4 (excellent), for a total score of 13-52, with higher scores indicating better QoL.[Longsdon 1996]. Score range is 13 (worst outcome) to 52 (best outcome).	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Grasp strength (Jamar dynamometer)	Measure of sustained power grasping force. Three readings on a Jamar dynamometer are averaged. Higher values indicate more abbility to grasp forcefully (a better outcome).	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Pinch strength (Jamar pinch meter)	Measure of sustained pinch force. Three readings on a Jamar pinch meter are averaged. Higher values indicate more abbility to pinch forcefully (a better outcome).	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Shoulder strength	Measure of deltoid muscle strength, measured using wrist weights. Higher values indicate more shoulder strength (a better outcome).	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Arm range of motion (goniometer)	Measure of upper extremity range of motion, measured using a mechanical goniometer. Higher values indicate more arm reach (a better outcome).	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Jebsen test of hand function	Timed battery of 7 simulated ADLs. Each task is timed with a stop watch, with faster tack execution being a better outcome. Score range for each task is 1 second (best) to 180 seconds (worst - unable to execute task).	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Chedokee test or independence in bimanual activities (CAHAI-9)	Test has 9 simulated bimanual activities. Each task is scored in the amount of assistance needed to execute it, with a score range for each task of 1 (worst) to 7 (best). Total score range is 9 (worst) to 63 (best).	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
University of Pennsylvania Smell Identification Test (UPSIT)	This test is a standardized measure of olfactory identification accuracy, done by scratching odor generating special paper. is also a four choice multiple choice question on each page. The scents are released using a pencil. After each scent is released, the patient smells the level and detects the odor from the four choices. Higher score indicate better olfaction (better outcome). Minimum score is 0, Maximum score is 40	at baseline, at 8 weeks from baseline (2 months),and at 16 weeks from baseline (4 months)
Subjective evaluation of BrightGo system and therapy	Subjective evaluation on a 5-point Likert scale of system and perceived benefits by participant and by caregiver. The score range is 1 (worst outcome) to 5 (best outcome)	For experimental group test is at 4, and 8 weeks from baseline. For cross-over controlles test is at 12 and 16 weeks from baseline.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cybersickness Susceptibility Questionnaire	Form used at screening post-consent to determine a participant's propensity for Determine propensity for simulation sickness [Freiwald et al 2020]. The questionnaire asks participants 13 general health and fitness questions (with yes/no answers) and to score 13 symptoms of cybersickness on a five point scale (0-4). Score range is 0 (best outcome - no likelihood of experiencing simulation sickness with the device) to 52 (worst outcome - certainty participant will experience severe simulation sickness).	at enrollment (20 minutes)
Montreal Cognitive Assessment (MoCA) to measure level of cognitive impairment	Used at screening post-consent to determine level of cognitive impairment [Nasreddine et al 2005] for participants. The form has a score range from 0 (worst) to 30 (best) - no cognitive impairments. The form will confirm a participant is in the score range of 19-25 range for early Alzheimer's disease.	at enrollment (20 minutes)
Pulse	Hart rate measured with medical meter	Before and after each of experimental session. For 3 months post-baseline for experimental group, or starting at 3 months from baseline for controll group. After cross over control group will take pulse for 3 months.
Blood pressure	Systolic and Diastolic Blood pressure, measured with medical meter	Before and after each of experimental session. For 3 months post-baseline for experimental group. For control group it starts at 3 months from baseline for 3 more months.
Game score	Score obtained by participant for each game played on the BrightGo system are converted to percent, with 0 percent being the worst outcome and 100 percent being the best outcome.	During each experimental session. For 2 months post-baseline for experimental group. For control group it starts at 3 months from baseline for 3 more months.
Head Movement	Obtained by participant Head Mounted Display during the BrightGo sessions.	During each experimental session. For 2 months post-baseline for experimental group. For control group it starts at 3 months from baseline for 3 more months.
Biosensor measure (eye blink)	Eye blink rates measured during game play.	During each experimental session. For 2 months post-baseline for experimental group. For control group it starts at 3 months from baseline for 3 more months.
Game difficulty	For each game played in an experimental session the system stores its difficulty level. This has a range of 1 (lowest difficulty) to 16 (highest difficulty)	During each experimental session. For 2 months post-baseline for experimental group. For control group it starts at 3 months from baseline for 3 more months.
Biosensor measure (skin resistance)	During an experimental session we store the skin resistance of the participant measured with a custom galvanic skin response system.	During each experimental session. For 2 months post-baseline for experimental group. For control group it starts at 3 months from baseline for 3 more months.

Collaborators and Investigators

• Sponsor: Bright Cloud International Corp
• Collaborators: National Institute on Aging (NIA); Rutgers, The State University of New Jersey
• Investigators: Principal Investigator: Grigore C. Burdea, PhD, Bright Cloud International

Study record dates

Study Major Dates

• Study Start (Actual): February 16, 2022
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): February 28, 2023

Study Registration Dates

• First Submitted: January 25, 2021
• First Submitted That Met QC Criteria: January 28, 2021
• First Posted (Actual): February 1, 2021

Study Record Updates

• Last Update Posted (Actual): May 2, 2022
• Last Update Submitted That Met QC Criteria: April 26, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: Elderly; Alzheimer's Disease; Caregiver; Virtual Reality; Exelon; Aricept; BrightGo
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Cholinergic Agents; Enzyme Inhibitors; Nootropic Agents; Cholinesterase Inhibitors; Donepezil
• Other Study ID Numbers: Telerehab AD Feasibility; R43AG065035 (NIH)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: We will not share individual participant's data

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No